Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 4:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 53 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: exposure to healthy labels only Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Antibody Response of Influenza Vaccination Following Concomitant Exposure to Bimekizumab in Healthy Subjects

NCT03895385
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2020 · Synced Oct 7, 2026, 4:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Influenza HA Ferritin Vaccine, Alone or in Prime-Boost Regimens With an Influenza DNA Vaccine in Healthy Adults

NCT03186781
View directory record Official record
Conditions
Influenza
Interventions
VRC-FLUNPF081-00-VP (HA-F A/Sing), VRC-FLUDNA082-00-VP (DNA A/Sing)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 16, 2021 · Synced Oct 7, 2026, 4:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s

NCT03457597
View directory record Official record
Conditions
Healthy
Interventions
Midazolam hydrochloride, Metoprolol tartrate, Pioglitazone hydrochloride, Tolbutamide, Omeprazole, Relacorilant
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 7, 2026, 4:08 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity Study of the Venezuelan Equine Encephalomyelitis Vaccine

NCT00582504
View directory record Official record
Conditions
Venezuelan Equine Encephalomyelitis
Interventions
VEE TC-83
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 65 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2022
U.S. locations
1
States / cities
Fort Deterick, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 7, 2026, 4:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Subjects to Determine the Effect of an Inhibitor on Exposure to Relacorilant and Its Metabolites

NCT03512548
View directory record Official record
Conditions
Healthy
Interventions
Relacorilant 350mg, Itraconazole, Relacorilant 300mg
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Oct 7, 2026, 4:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study of Avanfil in Healthy Young Male Subjects

NCT00914511
View directory record Official record
Conditions
Avanfil ADME, Semen Exposure, Sperm Function
Interventions
avanafil 200mg
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 7, 2011 · Synced Oct 7, 2026, 4:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relacorilant Food Effect Study in Healthy Subjects

NCT03442621
View directory record Official record
Conditions
Healthy, Food-drug Interaction
Interventions
Relacorilant Fasted, Relacorilant with a high fat breakfast, Relacorilant with a moderate breakfast
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 7, 2026, 4:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Drug-drug Interaction of BMS-963272 and Rosuvastatin

NCT04124003
View directory record Official record
Conditions
Healthy Participants
Interventions
rosuvastatin, BMS-963272
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Oct 7, 2026, 4:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Serum Testosterone and Nestorone in Females After Secondary Exposure to Nestorone ® (NES) + Testosterone (T) Combined Gel Applied to Shoulders and Upper Arms in Males

NCT02994602
View directory record Official record
Conditions
Healthy Men, Male Contraception, Healthy Women, Product Transference
Interventions
Nestorone + Testosterone Combination Gel
Drug
Lead sponsor
Kimberly Myer
Other
Eligibility
18 Years to 50 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Torrance, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 7, 2026, 4:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Vending Labeling Sales and Intercepts Study

NCT06260176
View directory record Official record
Conditions
Food Preferences, Obesity, Weight Gain
Interventions
exposure to healthy labels only, exposure to healthiness information, exposure to physical activity equivalents, exposure to sweetened beverage tax messaging
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
1,065 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 15, 2024 · Synced Oct 7, 2026, 4:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Randomized, Open-label, Single-dose, Single-center, Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of PT010

NCT03311373
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Regimen A, Regimen B, Regimen C, Regimen D
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 11, 2020 · Synced Oct 7, 2026, 4:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Trail for Intramuscular Administration of Midazolam Using An Autoinjector

NCT00534378
View directory record Official record
Conditions
Seizures
Interventions
Midazolam
Drug
Lead sponsor
U.S. Army Office of the Surgeon General
Federal
Eligibility
18 Years to 54 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2007 · Synced Oct 7, 2026, 4:08 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Immunology of Ebola Vaccine

NCT06100913
View directory record Official record
Conditions
Ebola Virus Disease
Interventions
Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP), Deuterium Labeled Water
Biological · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
2
States / cities
Decatur, Georgia • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 7, 2026, 4:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study in Healthy Volunteers

NCT01365117
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Technosphere® Insulin Inhalation Powder
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 14, 2012 · Synced Oct 7, 2026, 4:08 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 Cycles

NCT05139121
View directory record Official record
Conditions
Contraception
Interventions
MR-100A-01
Drug
Lead sponsor
Mylan Technologies Inc.
Industry
Eligibility
16 Years and older · Female only
Enrollment
1,320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
96
States / cities
Mobile, Alabama • Mesa, Arizona • Phoenix, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 7, 2026, 4:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)

NCT02859129
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
rosuvastatin 40 mg tablet, Epanova™ QD (2 x 1 g capsules), Multiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg dose, Multiple (20) oral doses of 2 g Vascepa® every 12 hours
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 17, 2016 · Synced Oct 7, 2026, 4:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of SIAN Nasal Spray in Healthy Adults

NCT05194358
View directory record Official record
Conditions
Cyanide Poisoning
Interventions
Stabilized Isoamyl Nitrite (SIAN)
Drug
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 45 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
Knoxville, Tennessee • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 7, 2026, 4:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Itraconazole on BCT197 Exposure in Healthy Male Participants

NCT03498170
View directory record Official record
Conditions
Interaction
Interventions
BCT197, Itraconazole 200 mg
Drug
Lead sponsor
Mereo BioPharma
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 18, 2018 · Synced Oct 7, 2026, 4:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effects of Fluvoxamine on Savolitinib Exposure in Healthy Male Subjects

NCT05888207
View directory record Official record
Conditions
Healthy Male Subjects
Interventions
Savolitinib, Fluvoxamine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Oct 7, 2026, 4:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Learn Safety and Blood Levels of PF-07817883 in Healthy People

NCT05580003
View directory record Official record
Conditions
Healthy
Interventions
PF-07817883, Placebo, Midazolam, Moxifloxacin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 7, 2026, 4:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Effect Study of AG120 in Healthy Subjects

NCT02579707
View directory record Official record
Conditions
Healthy
Interventions
AG120
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Oct 7, 2026, 4:08 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants

NCT07534592
View directory record Official record
Conditions
Healthy Participants
Interventions
Elecoglipron, Atorvastatin, Rosuvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 7, 2026, 4:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Mifepristone Drug-Drug Interaction Study With CYP3A Inhibitor

NCT03259542
View directory record Official record
Conditions
Drug Interaction Potentiation, Healthy
Interventions
Mifepristone 300 MG, Itraconazole 100 MG
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Oct 7, 2026, 4:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Pharmacokinetic Exposure of 2 Formulations of Apremilast in Healthy Adults

NCT02777554
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Apremilast IR, Apremilast XL
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 55 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
2
States / cities
Daytona Beach, Florida • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Oct 7, 2026, 4:08 AM EDT